(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/173605 A3

(51) International Patent Classification:
A61K 48/00 (2006.01) *A61P 3/00* (2006.01)
A61K 38/00 (2006.01)

(21) International Application Number:
PCT/US2022/014526

(22) International Filing Date:
31 January 2022 (31.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/148,093	10 February 2021 (10.02.2021)	US
63/180,361	27 April 2021 (27.04.2021)	US
63/210,610	15 June 2021 (15.06.2021)	US
63/242,250	09 September 2021 (09.09.2021)	US
63/256,805	18 October 2021 (18.10.2021)	US

(71) Applicant: **REGENXBIO INC.** [US/US]; 9804 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: **PAKOLA, Stephen, Joseph**; 15 Lewis Road, Irvington, NY 10533 (US). **FALABELLA, Paulo**; 12324 Overpond Way, Potomac, MD 20854 (US). **NEVORET, Marie-laure**; 328 Chesopeian Trail, Virginia Beach, VA 23452 (US).

(74) Agent: **MARTINEK, Sebastian** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
22 September 2022 (22.09.2022)

(54) Title: TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS)

(57) Abstract: Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).

WO 2022/173605 A3